MannKind Corp executive RSUs vest, 93,790 shares delivered

MannKind Corp Chief People & Workpl Officer Stuart A. Tross had a previously granted performance restricted stock unit award vest on July 15, 2026, delivering 93,790 shares of common stock.

Rhea-AI Filing Summary

MannKind Corp Chief People & Workpl Officer Stuart A. Tross had a previously granted performance restricted stock unit award vest on July 15, 2026, delivering 93,790 shares of common stock. To cover taxes, a total of 65,808 shares were withheld at $4.09 per share, and his direct holdings include shares acquired through the Employee Stock Purchase Plan.

Insider Trade Summary

93,790 shares exercised/converted

Exercise 6 txns

Insider Tross Stuart A

Role Chief People & Workpl Officer

Type	Security	Shares	Price	Value
Exercise	Performance Restricted Stock Unit F4, F1	93,790	$0.00	$0.00
Exercise	Common Stock, $0.01 Par Value F1, F2	93,790	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock, $0.01 Par Value F3	33,652	$4.09	$138K
Exercise Price or Tax Liability	Common Stock, $0.01 Par Value F3	8,253	$4.09	$34K
Exercise Price or Tax Liability	Common Stock, $0.01 Par Value F3	11,572	$4.09	$47K
Exercise Price or Tax Liability	Common Stock, $0.01 Par Value F3	12,331	$4.09	$50K

Holdings After Transaction: Performance Restricted Stock Unit — 0 contracts (Direct); Common Stock, $0.01 Par Value — 1,058,142 shares (Direct)

Footnotes (4)

1. F1. A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
2. F2. Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
3. F3. Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
4. F4. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

Key Figures

Performance RSUs vested: 93,790 shares Original RSU grant: 113,000 shares Forfeited RSUs: 19,210 shares +5 more

8 metrics

Performance RSUs vested 93,790 shares Shares delivered upon vesting of performance restricted stock unit award on July 15, 2026

Original RSU grant 113,000 shares Restricted stock unit award granted on May 25, 2023

Forfeited RSUs 19,210 shares Remaining shares forfeited under performance vesting criteria after 83% target achievement

Tax withholding shares 65,808 shares Shares delivered or withheld to pay exercise price or tax liability incident to RSU vesting

Tax withholding price $4.09 per share Per-share price for common stock used in tax-withholding (F-code) transactions

TSR percentile 41.5th percentile MannKind’s total shareholder return vs Russell 3000 Pharmaceutical & Biotechnology Index

Performance objective achievement 83% of target Level at which performance objectives for RSU vesting were achieved

ESPP shares acquired 4,038 shares Shares acquired under the Employee Stock Purchase Plan on June 30, 2026

Key Terms

Performance Restricted Stock Unit, total shareholder return (TSR), Russell 3000 Pharmaceutical & Biotechnology Index, Employee Stock Purchase Plan, +1 more

5 terms

Performance Restricted Stock Unit financial

"A Performance Restricted Stock Unit award vested, delivering common shares."

total shareholder return (TSR) financial

"MannKind's total shareholder return (TSR) was at the 41.5th percentile."

Total shareholder return (TSR) measures how much an investment in a company's stock has grown over a specific period by combining the change in the share price and all dividends paid, expressed as a percentage. Think of it like tracking the total balance of a savings jar that increases both from added cash (dividends) and a rising sticker price on the jar (share price); investors use TSR to compare how well different stocks or managers deliver real, money-in-hand returns.

Russell 3000 Pharmaceutical & Biotechnology Index financial

"TSR was measured against the Russell 3000 Pharmaceutical & Biotechnology Index."

Employee Stock Purchase Plan financial

"Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3 regulatory

"Shares were withheld incident to vesting in accordance with Rule 16b-3."

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What RSU vesting did MannKind Corp (MNKD) report for Stuart A. Tross?

MannKind reported that a performance restricted stock unit award for Stuart A. Tross vested on July 15, 2026, delivering 93,790 shares of common stock after achieving performance objectives at 83% of target under criteria set in May 2023.

How many shares were withheld for taxes in MannKind (MNKD)'s Form 4?

The Form 4 shows that 65,808 shares of MannKind common stock were delivered or withheld to pay exercise price or tax liabilities, in several transactions priced at $4.09 per share, incident to the vesting of previously reported restricted stock units.

What performance goals triggered RSU vesting for MNKD's Chief People & Workpl Officer?

The RSUs vested after two goals were met: the closing price of MannKind common stock on June 30, 2026 was not less than on May 25, 2023, and total shareholder return reached the 41.5th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index, yielding 83% of target.

Were any RSU shares forfeited in MannKind (MNKD)'s latest Form 4?

Yes. The original restricted stock unit award covered 113,000 shares, but performance objectives were achieved at 83% of target, resulting in delivery of 93,790 shares and forfeiture of the remaining 19,210 shares under the performance vesting criteria.

What additional shares does Stuart A. Tross hold from MannKind (MNKD)'s ESPP?

A footnote states that Tross’s direct common stock holdings include 4,038 shares acquired under MannKind’s Employee Stock Purchase Plan on June 30, 2026, in addition to shares received from the vesting of performance restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 09:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tross Stuart A

(Last) (First) (Middle)

1 CASPER STREET

(Street)

DANBURY CONNECTICUT 06810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MANNKIND CORP [ MNKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People & Workpl Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 Par Value	07/15/2026		M(1)		93,790	A	$0	1,123,950(2)	D
Common Stock, $0.01 Par Value	07/15/2026		F(3)		33,652	D	$4.09	1,090,298	D
Common Stock, $0.01 Par Value	07/15/2026		F(3)		8,253	D	$4.09	1,082,045	D
Common Stock, $0.01 Par Value	07/15/2026		F(3)		11,572	D	$4.09	1,070,473	D
Common Stock, $0.01 Par Value	07/15/2026		F(3)		12,331	D	$4.09	1,058,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Restricted Stock Unit	(4)	07/15/2026		M(1)			93,790	(1)	(1)	Common Stock, $0.01 Par Value	93,790	$0	0(1)	D

Explanation of Responses:

1. A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.

2. Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.

3. Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.

4. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

	/s/ Stuart A. Tross	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)